NEW YORK (GenomeWeb) – As the US Department of Health and Human Services (HHS) mulls whether or not to recommend nationwide screening for newborn spinal muscular atrophy (SMA), stakeholders continue to push for the genetic disease to be included in the recommended newborn screening panel.

Meanwhile, SMA screening options are growing, as the US Centers for Disease Control and Prevention has developed and published a PCR-based assay for the condition, while PerkinElmer is developing a testing kit for potential commercial use.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.